What is Mucuna Pruriens?

Mucuna pruriens (MP), a naturally levodopa-rich plant, has gained renewed interest as both a traditional medicine and a potential treatment for Parkinson’s disease.

In low- and middle-income countries (LMICs), MP may represent a cost-effective, locally cultivable alternative where access to levodopa-based medications is limited. In high-income countries, patients often seek it out as a natural alternative. While clinical evidence indicates processed MP is as effective as commercial levodopa for short-term symptom relief, long-term safety is not yet proven. Crucially, MP requires strict caution.

Unmonitored self-treatment can cause serious side effects, including dyskinesia, addiction-like behaviors, psychiatric issues, and toxicity from poor preparation. Therefore, MP should currently be restricted to clinical trials or specialist-guided treatment, even if its potential for resource-poor regions remains high.

TraPCAf's Position on Mucuna Pruriens

Mucuna is not a replacement for prescribed levodopa or standard Parkinson’s medications. Evidence-based clinical guidelines remain the standard of care for managing all stages of Parkinson’s disease. As Mucuna is not part of any national treatment guidelines, most specialists consider it a complementary therapy rather than a primary treatment.

Anyone considering Mucuna should discuss it with their doctor first. This information is purely educational and should not replace professional medical advice. TraPCAf physicians do not endorse using Mucuna instead of prescribed levodopa/carbidopa or other established Parkinson’s treatments.

Resources

Mucuna Pruriens: What We Know So Far | Transforming Parkinson's Care in Africa (TraPCAf) Webinar

Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial (DOI: 10.1177/1877718X251383721)

Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials (DOI: 10.1016/j.parkreldis.2024.106983)

“To Bean or Not to Bean”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens (DOI: 10.1177/1877718X261442075)

Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile (DOI: 10.1016/j.jns.2016.04.001)

Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database (DOI: 10.1001/jamaneurol.2022.2184)

Mucuna and Parkinson’s Disease: Treatment with Natural Levodopa (DOI: 10.5772/intechopen.74062)

Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters (DOI: 10.1002/ptr.1407)

Zandu Pharmaceutical Works Ltd. (HP-200)